Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
5.2
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales10,728¥ millionYear on year +5.2%Progress 25.5%
Operating profit667¥ millionYear on year -16.7%Progress 21.7%
Ordinary income640¥ millionYear on year -21.3%Progress 22.1%
Net income attributable to owners of the parent445¥ millionYear on year -25.8%Progress 21.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥13.52
Financial position at period-end
Total assets61,895¥ million
of which net assets 43,497 ¥ millionEquity ratio 70.1%vs. prior year-end 0.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Regional sales¥3,175 million (YoY +14.9%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥42,000 million (YoY +0.2%)
Operating profit¥3,070 million (YoY +5.2%)
Ordinary income¥2,900 million (YoY +2.0%)
Net income¥2,070 million (YoY -44.2%)
Annual Dividend Forecast¥58 → ¥58（0.0%）
Factors Behind Changes in Business Performance
Overseas sales remained solid, with sales of fecal occult blood testing reagents driving overseas revenue. Profit, however, was affected by changes in the sales mix and soaring raw material prices, among other factors.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Gain on sale of non-current assets ¥0 million, Loss on disposal and sale of non-current assets ¥0 million
Depreciation and amortization¥606 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End34,541,438 Shares
Treasury Shares at Period-End1,575,865 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥10,728 million (YoY +5.2%) |
| Operating profit | ¥667 million (YoY -16.7%) |
| Ordinary income | ¥640 million (YoY -21.3%) |
| Profit attributable to owners of the parent | ¥445 million (YoY -25.8%) |
| Net income per share | ¥13.52 |
| Equity ratio | End of the current fiscal period 70.1 / End of previous period 70.1 |
| Total assets | ¥61,895 million |
| Net assets | ¥43,497 million |
| Full-year earnings forecast | Net Sales ¥42,000 million (YoY +0.2%) / Operating profit ¥3,070 million (YoY +5.2%) / Ordinary income ¥2,900 million (YoY +2.0%) / Net income ¥2,070 million (YoY -44.2%) |
| Annual Dividend Forecast | ¥58 → ¥58（0.0%） |
| Regional sales | ¥3,175 million (YoY +14.9%) |
| Depreciation and amortization | ¥606 million |
| Breakdown of extraordinary income (loss) | Gain on sale of non-current assets ¥0 million, Loss on disposal and sale of non-current assets ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 34,541,438 Shares |
| Treasury Shares at Period-End | 1,575,865 Shares |
| Factors Behind Changes in Business Performance | Overseas sales remained solid, with sales of fecal occult blood testing reagents driving overseas revenue. Profit, however, was affected by changes in the sales mix and soaring raw material prices, among other factors. |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased as overseas sales remained solid. Profit was affected by changes in the sales mix and soaring raw material prices, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.